Intrust Bank NA boosted its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 10.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 26,764 shares of the biopharmaceutical company's stock after purchasing an additional 2,435 shares during the period. Intrust Bank NA's holdings in Gilead Sciences were worth $2,472,000 at the end of the most recent reporting period.
Other hedge funds also recently added to or reduced their stakes in the company. Bellevue Group AG lifted its holdings in Gilead Sciences by 18.2% in the 3rd quarter. Bellevue Group AG now owns 46,027 shares of the biopharmaceutical company's stock worth $3,859,000 after buying an additional 7,093 shares in the last quarter. Quantinno Capital Management LP lifted its stake in shares of Gilead Sciences by 149.5% in the third quarter. Quantinno Capital Management LP now owns 81,620 shares of the biopharmaceutical company's stock worth $6,843,000 after acquiring an additional 48,910 shares in the last quarter. McAdam LLC boosted its holdings in Gilead Sciences by 16.7% in the fourth quarter. McAdam LLC now owns 25,372 shares of the biopharmaceutical company's stock valued at $2,344,000 after purchasing an additional 3,627 shares during the last quarter. Capital Investment Advisors LLC grew its stake in Gilead Sciences by 2.6% during the 4th quarter. Capital Investment Advisors LLC now owns 387,492 shares of the biopharmaceutical company's stock valued at $35,793,000 after purchasing an additional 9,791 shares in the last quarter. Finally, Empirical Financial Services LLC d.b.a. Empirical Wealth Management raised its position in shares of Gilead Sciences by 3.9% in the 4th quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 142,167 shares of the biopharmaceutical company's stock valued at $13,132,000 after purchasing an additional 5,382 shares in the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
A number of research analysts have commented on GILD shares. DZ Bank upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 price objective on the stock in a research note on Thursday, February 13th. JPMorgan Chase & Co. increased their price target on shares of Gilead Sciences from $120.00 to $130.00 and gave the stock an "overweight" rating in a research report on Thursday, March 27th. Piper Sandler boosted their price objective on Gilead Sciences from $105.00 to $110.00 and gave the company an "overweight" rating in a report on Wednesday, February 12th. BMO Capital Markets increased their target price on Gilead Sciences from $110.00 to $115.00 and gave the stock an "outperform" rating in a report on Wednesday, February 12th. Finally, Cantor Fitzgerald reiterated a "neutral" rating and issued a $80.00 price target on shares of Gilead Sciences in a report on Wednesday, December 11th. Eleven research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $105.12.
Read Our Latest Stock Report on GILD
Gilead Sciences Price Performance
Shares of Gilead Sciences stock traded down $0.77 during trading on Tuesday, hitting $111.28. The stock had a trading volume of 6,275,159 shares, compared to its average volume of 7,287,902. The business has a fifty day moving average of $105.88 and a two-hundred day moving average of $95.20. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $119.96. The firm has a market cap of $138.58 billion, a P/E ratio of 300.76, a PEG ratio of 0.71 and a beta of 0.21. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. On average, sell-side analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.
Gilead Sciences Increases Dividend
The business also recently declared a quarterly dividend, which was paid on Friday, March 28th. Investors of record on Friday, March 14th were paid a $0.79 dividend. The ex-dividend date was Friday, March 14th. This represents a $3.16 dividend on an annualized basis and a yield of 2.84%. This is a boost from Gilead Sciences's previous quarterly dividend of $0.77. Gilead Sciences's dividend payout ratio (DPR) is currently 854.05%.
Insider Buying and Selling at Gilead Sciences
In other Gilead Sciences news, CFO Andrew D. Dickinson sold 142,180 shares of the business's stock in a transaction on Friday, January 31st. The shares were sold at an average price of $97.22, for a total transaction of $13,822,739.60. Following the sale, the chief financial officer now directly owns 129,873 shares of the company's stock, valued at $12,626,253.06. The trade was a 52.26 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Over the last ninety days, insiders sold 302,785 shares of company stock valued at $30,503,250. 0.16% of the stock is currently owned by corporate insiders.
Gilead Sciences Company Profile
(
Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Featured Articles
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
